SILDENAFIL CITRATE IN THE TREATMENT OF MEN WITH ERECTILE DYSFUNCTION


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Based on literature data and the results of own authors’ research, the review article considers the efficacy and safety of sildenafil, including its long-term use. Application of this drug leads to an improvement of erectile function in patients of all ages, regardless of etiology, severity and duration of erectile dysfunction (ED). Drug has long-term efficacy. Sildenafil affects both arterial and venous blood flow to the penis, which makes it indicated in vasculogenic erectile dysfunction first. Treatment with sildenafil is accompanied by improvement of the cavernous electrical activity, which justifies its use in neurogenic form of the disease. According to results of IIEF questionnaire, sildenafil provides quick and lasting therapeutic effect. Efficacy and safety of sildenafil is rated as good. As for short-term and long-term use, sildenafil does not cause dependence and addiction.

全文:

受限制的访问

作者简介

S. Gamidov

FSBI "Scientific Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov" of RMPH; SBEI HPE "First Moscow State Medical University n.a. I.M. Sechenov" of RMPH; SBEI HPE "Russian National Scientific Medical University n.a. N.I. Pirogov" of RMPH

R. Ovchinnikov

FSBI "Scientific Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov" of RMPH

Email: r_ovchinnikov@oparina4.ru
PhD in Medical Sciences, Head of the Department of Andrology and Urology

A. Popova

FSBI "Scientific Center for Obstetrics, Gynecology and Perinatology n.a. Academician V.I. Kulakov" of RMPH; SBEI HPE "First Moscow State Medical University n.a. I.M. Sechenov" of RMPH

参考

  1. Feldman H.A. et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol. 1994; 151:54-56.
  2. Lue T.F. Erectile dysfunction: problems and challenges. J Urol. 1993; 149: 1256-1257.
  3. Кротовский Г.С., Зудин A.M. Виагра - 5 лет успеха. М., 2003. 189 с.
  4. Morales A., Heaton J.P.W., Johnston B., Adams M. Oral and topical treatment of erectile dysfunction: present and future. Urol Clin North Am. 1995; 22: 879-886.
  5. Wespes E., Amar E., Hatzichristou D. et al. EAU Guidelines on Erectile Dysfunction: An Update. Eur Urol. 2006; 49: 806-815.
  6. Krane R.J. Changes in ED therapy in the Viagra era. World J Urol. 2001; 19:23-24.
  7. Carson C.C., Burnett A.L., Levine L.A. et al. The efficacy of Sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002; 60: 12-27.
  8. Vandi Y., Klein L., Nassar S. et al. Effects of Sildenafil citrate on blood pressure in normotensive and hypertensive men. Urology. 2002; 59: 747-752.
  9. Kloner R.A., Brown M., Prisant L.M. et al. Effects of Sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens. 2001; 14: 70-73.
  10. Numberg H.G., Seidman S.N., Gelenberg A.J. et al. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of Sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology. 2002; 60: 58-66.
  11. Fowler C.J., Miller J.R., Sharief M.K. et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005; 76: 700-705.
  12. Raina R., Laken M.M., Agarwal A. et al. Long-term effect of Sildenafil citrate on erectile dysfunction after radical prostatectomy: a 3-year follow-up. Urology. 2003; 62:110-115.
  13. Begg C.B., Riedel E.R., Bach P.B. et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002; 346:1138-1144.
  14. McCullough A.R., Barada J.H., Fawzy A. et al. Achieving treatment optimization with Sildenafil citrate in patients with erectile function. Urology. 2002; 60:28-37.
  15. Eisenhardt A., Siffert W. Genetic risk factors for erectile dysfunction and genetic determinants of drug response - on the way to improve drug safety? Herz. 2003; 28: 304-313.
  16. Steers W.D. Tachyphylaxis and phosphodiesterase type 5 inhibitors. J Urol. 2002;168:207-209.
  17. Carson C.C. Sildenafil citrate treatment for erectile dysfunction: rate of adverse events decreases with time. J Urol. 2002;167 (Suppl.):179-183.
  18. Sariam K., Kulinsbaya E., McNicholas T.A. et al. Sildenafil influences lower urinary tract symptoms. BIU Int. 2002; 90: 836-839.
  19. Giuliano F., Jackson G., Montorsi F., Martin-Morales A., Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010; 64(2):240-255.
  20. McMurray J.G., Feldman R.A., Auerbach S.M. et al. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag. 2007;3:975-981.
  21. Christiansen E., Guirguis W.R., Cox D., Osterloh I.H. Sildenafil Multicentre Study Group. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res. 2000; 12(3): 177-182.
  22. El-Galley R., Rutland H., Talic R. et al. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001;166(3):927-931.
  23. Овчинников Р.И., Гамидов С.И., Мазо Е.Б. Влияние фармакотерапии эректильной дисфункции на кавернозную электрическую активность и гемодинамику полового члена. Материалы Федерального конгресса «Сексуальное здоровье мужчины. Текущие интересы науки и здравоохранения». Ростов, Россия, 26-27.09.2013. С. 69-70.
  24. Mulhall J.P. Understanding erectile dysfunction medication preference studies. Curr Opin Urol. 2004;14:367-373.
  25. Тевлин К.Б., Брук Ю.Ф. Вопросы выбора ингибитора ФДЭ-5: эффективность и безопасность. Экспериментальная и клиническая урология. 2013;2:46-50.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014